Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma

Recruiting now

Conditions studied: Esophageal Cancer, Recurrence, DNA Methylation

In brief

The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.

Key facts

Study ID

NCT06476067

Run by

City of Hope Medical Center

People needed

150

Starts

2006-01-01

Expected to finish

2028-06-18

Last updated by the study team

2026-07-13

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who had histologically confirmed ESCC.
• Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.
• Patients for whom tissue samples are available
• Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.
• Written informed consent following full study information is provided to the patient.

You may not qualify if…

• Patients lacking clinical information within 2 years of surgery.
• Patients with multiple cancers.

Where it is running

• Nagoya University — Nagoya, Aichi-ken, Japan (enrolling)
• Yamanashi Universiy — Chūō, Yamanashi, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.